Animal models for liver disease – A practical approach for translational research
Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from ea...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Nevzorova, Yulia A. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
18 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Identification of the antigenic region of - Abdelbaky, Hanan H. ELSEVIER, 2018, official journal of the European Association for the Study of the Liver, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:73 ; year:2020 ; number:2 ; pages:423-440 ; extent:18 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jhep.2020.04.011 |
|---|
| Katalog-ID: |
ELV050848755 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV050848755 | ||
| 003 | DE-627 | ||
| 005 | 20230626031230.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200722s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jhep.2020.04.011 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001074.pica |
| 035 | |a (DE-627)ELV050848755 | ||
| 035 | |a (ELSEVIER)S0168-8278(20)30223-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.44 |2 bkl | ||
| 100 | 1 | |a Nevzorova, Yulia A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Animal models for liver disease – A practical approach for translational research |
| 264 | 1 | |c 2020transfer abstract | |
| 300 | |a 18 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from early stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing the advantages and weaknesses of available models for researchers who are planning to perform animal studies in the near future. Additionally, we summarise current and prospective models based on human tissue bioengineering. | ||
| 520 | |a Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from early stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing the advantages and weaknesses of available models for researchers who are planning to perform animal studies in the near future. Additionally, we summarise current and prospective models based on human tissue bioengineering. | ||
| 650 | 7 | |a Cirrhosis |2 Elsevier | |
| 650 | 7 | |a NAFLD |2 Elsevier | |
| 650 | 7 | |a Primary liver cancer |2 Elsevier | |
| 650 | 7 | |a Fibrosis |2 Elsevier | |
| 650 | 7 | |a ALD |2 Elsevier | |
| 650 | 7 | |a Non-alcoholic fatty liver disease |2 Elsevier | |
| 650 | 7 | |a Non-alcoholic steatohepatitis |2 Elsevier | |
| 650 | 7 | |a NASH |2 Elsevier | |
| 700 | 1 | |a Boyer-Diaz, Zoe |4 oth | |
| 700 | 1 | |a Cubero, Francisco Javier |4 oth | |
| 700 | 1 | |a Gracia-Sancho, Jordi |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Abdelbaky, Hanan H. ELSEVIER |t Identification of the antigenic region of |d 2018 |d official journal of the European Association for the Study of the Liver |g Amsterdam [u.a.] |w (DE-627)ELV000433829 |
| 773 | 1 | 8 | |g volume:73 |g year:2020 |g number:2 |g pages:423-440 |g extent:18 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jhep.2020.04.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.44 |j Parasitologie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 73 |j 2020 |e 2 |h 423-440 |g 18 | ||
| author_variant |
y a n ya yan |
|---|---|
| matchkey_str |
nevzorovayuliaaboyerdiazzoecuberofrancis:2020----:nmloesolvriesarciaapocfrr |
| hierarchy_sort_str |
2020transfer abstract |
| bklnumber |
44.44 |
| publishDate |
2020 |
| allfields |
10.1016/j.jhep.2020.04.011 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001074.pica (DE-627)ELV050848755 (ELSEVIER)S0168-8278(20)30223-3 DE-627 ger DE-627 rakwb eng 610 VZ 44.44 bkl Nevzorova, Yulia A. verfasserin aut Animal models for liver disease – A practical approach for translational research 2020transfer abstract 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from early stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing the advantages and weaknesses of available models for researchers who are planning to perform animal studies in the near future. Additionally, we summarise current and prospective models based on human tissue bioengineering. Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from early stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing the advantages and weaknesses of available models for researchers who are planning to perform animal studies in the near future. Additionally, we summarise current and prospective models based on human tissue bioengineering. Cirrhosis Elsevier NAFLD Elsevier Primary liver cancer Elsevier Fibrosis Elsevier ALD Elsevier Non-alcoholic fatty liver disease Elsevier Non-alcoholic steatohepatitis Elsevier NASH Elsevier Boyer-Diaz, Zoe oth Cubero, Francisco Javier oth Gracia-Sancho, Jordi oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:73 year:2020 number:2 pages:423-440 extent:18 https://doi.org/10.1016/j.jhep.2020.04.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 73 2020 2 423-440 18 |
| spelling |
10.1016/j.jhep.2020.04.011 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001074.pica (DE-627)ELV050848755 (ELSEVIER)S0168-8278(20)30223-3 DE-627 ger DE-627 rakwb eng 610 VZ 44.44 bkl Nevzorova, Yulia A. verfasserin aut Animal models for liver disease – A practical approach for translational research 2020transfer abstract 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from early stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing the advantages and weaknesses of available models for researchers who are planning to perform animal studies in the near future. Additionally, we summarise current and prospective models based on human tissue bioengineering. Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from early stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing the advantages and weaknesses of available models for researchers who are planning to perform animal studies in the near future. Additionally, we summarise current and prospective models based on human tissue bioengineering. Cirrhosis Elsevier NAFLD Elsevier Primary liver cancer Elsevier Fibrosis Elsevier ALD Elsevier Non-alcoholic fatty liver disease Elsevier Non-alcoholic steatohepatitis Elsevier NASH Elsevier Boyer-Diaz, Zoe oth Cubero, Francisco Javier oth Gracia-Sancho, Jordi oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:73 year:2020 number:2 pages:423-440 extent:18 https://doi.org/10.1016/j.jhep.2020.04.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 73 2020 2 423-440 18 |
| allfields_unstemmed |
10.1016/j.jhep.2020.04.011 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001074.pica (DE-627)ELV050848755 (ELSEVIER)S0168-8278(20)30223-3 DE-627 ger DE-627 rakwb eng 610 VZ 44.44 bkl Nevzorova, Yulia A. verfasserin aut Animal models for liver disease – A practical approach for translational research 2020transfer abstract 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from early stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing the advantages and weaknesses of available models for researchers who are planning to perform animal studies in the near future. Additionally, we summarise current and prospective models based on human tissue bioengineering. Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from early stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing the advantages and weaknesses of available models for researchers who are planning to perform animal studies in the near future. Additionally, we summarise current and prospective models based on human tissue bioengineering. Cirrhosis Elsevier NAFLD Elsevier Primary liver cancer Elsevier Fibrosis Elsevier ALD Elsevier Non-alcoholic fatty liver disease Elsevier Non-alcoholic steatohepatitis Elsevier NASH Elsevier Boyer-Diaz, Zoe oth Cubero, Francisco Javier oth Gracia-Sancho, Jordi oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:73 year:2020 number:2 pages:423-440 extent:18 https://doi.org/10.1016/j.jhep.2020.04.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 73 2020 2 423-440 18 |
| allfieldsGer |
10.1016/j.jhep.2020.04.011 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001074.pica (DE-627)ELV050848755 (ELSEVIER)S0168-8278(20)30223-3 DE-627 ger DE-627 rakwb eng 610 VZ 44.44 bkl Nevzorova, Yulia A. verfasserin aut Animal models for liver disease – A practical approach for translational research 2020transfer abstract 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from early stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing the advantages and weaknesses of available models for researchers who are planning to perform animal studies in the near future. Additionally, we summarise current and prospective models based on human tissue bioengineering. Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from early stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing the advantages and weaknesses of available models for researchers who are planning to perform animal studies in the near future. Additionally, we summarise current and prospective models based on human tissue bioengineering. Cirrhosis Elsevier NAFLD Elsevier Primary liver cancer Elsevier Fibrosis Elsevier ALD Elsevier Non-alcoholic fatty liver disease Elsevier Non-alcoholic steatohepatitis Elsevier NASH Elsevier Boyer-Diaz, Zoe oth Cubero, Francisco Javier oth Gracia-Sancho, Jordi oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:73 year:2020 number:2 pages:423-440 extent:18 https://doi.org/10.1016/j.jhep.2020.04.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 73 2020 2 423-440 18 |
| allfieldsSound |
10.1016/j.jhep.2020.04.011 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001074.pica (DE-627)ELV050848755 (ELSEVIER)S0168-8278(20)30223-3 DE-627 ger DE-627 rakwb eng 610 VZ 44.44 bkl Nevzorova, Yulia A. verfasserin aut Animal models for liver disease – A practical approach for translational research 2020transfer abstract 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from early stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing the advantages and weaknesses of available models for researchers who are planning to perform animal studies in the near future. Additionally, we summarise current and prospective models based on human tissue bioengineering. Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from early stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing the advantages and weaknesses of available models for researchers who are planning to perform animal studies in the near future. Additionally, we summarise current and prospective models based on human tissue bioengineering. Cirrhosis Elsevier NAFLD Elsevier Primary liver cancer Elsevier Fibrosis Elsevier ALD Elsevier Non-alcoholic fatty liver disease Elsevier Non-alcoholic steatohepatitis Elsevier NASH Elsevier Boyer-Diaz, Zoe oth Cubero, Francisco Javier oth Gracia-Sancho, Jordi oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:73 year:2020 number:2 pages:423-440 extent:18 https://doi.org/10.1016/j.jhep.2020.04.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 73 2020 2 423-440 18 |
| language |
English |
| source |
Enthalten in Identification of the antigenic region of Amsterdam [u.a.] volume:73 year:2020 number:2 pages:423-440 extent:18 |
| sourceStr |
Enthalten in Identification of the antigenic region of Amsterdam [u.a.] volume:73 year:2020 number:2 pages:423-440 extent:18 |
| format_phy_str_mv |
Article |
| bklname |
Parasitologie |
| institution |
findex.gbv.de |
| topic_facet |
Cirrhosis NAFLD Primary liver cancer Fibrosis ALD Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis NASH |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Identification of the antigenic region of |
| authorswithroles_txt_mv |
Nevzorova, Yulia A. @@aut@@ Boyer-Diaz, Zoe @@oth@@ Cubero, Francisco Javier @@oth@@ Gracia-Sancho, Jordi @@oth@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000433829 |
| dewey-sort |
3610 |
| id |
ELV050848755 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV050848755</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626031230.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200722s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jhep.2020.04.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001074.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV050848755</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0168-8278(20)30223-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Nevzorova, Yulia A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Animal models for liver disease – A practical approach for translational research</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">18</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from early stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing the advantages and weaknesses of available models for researchers who are planning to perform animal studies in the near future. Additionally, we summarise current and prospective models based on human tissue bioengineering.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from early stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing the advantages and weaknesses of available models for researchers who are planning to perform animal studies in the near future. Additionally, we summarise current and prospective models based on human tissue bioengineering.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cirrhosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NAFLD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Primary liver cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Fibrosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ALD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Non-alcoholic fatty liver disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Non-alcoholic steatohepatitis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NASH</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Boyer-Diaz, Zoe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cubero, Francisco Javier</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gracia-Sancho, Jordi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Abdelbaky, Hanan H. ELSEVIER</subfield><subfield code="t">Identification of the antigenic region of</subfield><subfield code="d">2018</subfield><subfield code="d">official journal of the European Association for the Study of the Liver</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000433829</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:73</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:423-440</subfield><subfield code="g">extent:18</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jhep.2020.04.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">73</subfield><subfield code="j">2020</subfield><subfield code="e">2</subfield><subfield code="h">423-440</subfield><subfield code="g">18</subfield></datafield></record></collection>
|
| author |
Nevzorova, Yulia A. |
| spellingShingle |
Nevzorova, Yulia A. ddc 610 bkl 44.44 Elsevier Cirrhosis Elsevier NAFLD Elsevier Primary liver cancer Elsevier Fibrosis Elsevier ALD Elsevier Non-alcoholic fatty liver disease Elsevier Non-alcoholic steatohepatitis Elsevier NASH Animal models for liver disease – A practical approach for translational research |
| authorStr |
Nevzorova, Yulia A. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000433829 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.44 bkl Animal models for liver disease – A practical approach for translational research Cirrhosis Elsevier NAFLD Elsevier Primary liver cancer Elsevier Fibrosis Elsevier ALD Elsevier Non-alcoholic fatty liver disease Elsevier Non-alcoholic steatohepatitis Elsevier NASH Elsevier |
| topic |
ddc 610 bkl 44.44 Elsevier Cirrhosis Elsevier NAFLD Elsevier Primary liver cancer Elsevier Fibrosis Elsevier ALD Elsevier Non-alcoholic fatty liver disease Elsevier Non-alcoholic steatohepatitis Elsevier NASH |
| topic_unstemmed |
ddc 610 bkl 44.44 Elsevier Cirrhosis Elsevier NAFLD Elsevier Primary liver cancer Elsevier Fibrosis Elsevier ALD Elsevier Non-alcoholic fatty liver disease Elsevier Non-alcoholic steatohepatitis Elsevier NASH |
| topic_browse |
ddc 610 bkl 44.44 Elsevier Cirrhosis Elsevier NAFLD Elsevier Primary liver cancer Elsevier Fibrosis Elsevier ALD Elsevier Non-alcoholic fatty liver disease Elsevier Non-alcoholic steatohepatitis Elsevier NASH |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
z b d zbd f j c fj fjc j g s jgs |
| hierarchy_parent_title |
Identification of the antigenic region of |
| hierarchy_parent_id |
ELV000433829 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Identification of the antigenic region of |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000433829 |
| title |
Animal models for liver disease – A practical approach for translational research |
| ctrlnum |
(DE-627)ELV050848755 (ELSEVIER)S0168-8278(20)30223-3 |
| title_full |
Animal models for liver disease – A practical approach for translational research |
| author_sort |
Nevzorova, Yulia A. |
| journal |
Identification of the antigenic region of |
| journalStr |
Identification of the antigenic region of |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
zzz |
| container_start_page |
423 |
| author_browse |
Nevzorova, Yulia A. |
| container_volume |
73 |
| physical |
18 |
| class |
610 VZ 44.44 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Nevzorova, Yulia A. |
| doi_str_mv |
10.1016/j.jhep.2020.04.011 |
| dewey-full |
610 |
| title_sort |
animal models for liver disease – a practical approach for translational research |
| title_auth |
Animal models for liver disease – A practical approach for translational research |
| abstract |
Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from early stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing the advantages and weaknesses of available models for researchers who are planning to perform animal studies in the near future. Additionally, we summarise current and prospective models based on human tissue bioengineering. |
| abstractGer |
Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from early stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing the advantages and weaknesses of available models for researchers who are planning to perform animal studies in the near future. Additionally, we summarise current and prospective models based on human tissue bioengineering. |
| abstract_unstemmed |
Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from early stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing the advantages and weaknesses of available models for researchers who are planning to perform animal studies in the near future. Additionally, we summarise current and prospective models based on human tissue bioengineering. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
2 |
| title_short |
Animal models for liver disease – A practical approach for translational research |
| url |
https://doi.org/10.1016/j.jhep.2020.04.011 |
| remote_bool |
true |
| author2 |
Boyer-Diaz, Zoe Cubero, Francisco Javier Gracia-Sancho, Jordi |
| author2Str |
Boyer-Diaz, Zoe Cubero, Francisco Javier Gracia-Sancho, Jordi |
| ppnlink |
ELV000433829 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.jhep.2020.04.011 |
| up_date |
2024-07-06T18:38:24.087Z |
| _version_ |
1803855964760178688 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV050848755</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626031230.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200722s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jhep.2020.04.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001074.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV050848755</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0168-8278(20)30223-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Nevzorova, Yulia A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Animal models for liver disease – A practical approach for translational research</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">18</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from early stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing the advantages and weaknesses of available models for researchers who are planning to perform animal studies in the near future. Additionally, we summarise current and prospective models based on human tissue bioengineering.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from early stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing the advantages and weaknesses of available models for researchers who are planning to perform animal studies in the near future. Additionally, we summarise current and prospective models based on human tissue bioengineering.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cirrhosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NAFLD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Primary liver cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Fibrosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ALD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Non-alcoholic fatty liver disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Non-alcoholic steatohepatitis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NASH</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Boyer-Diaz, Zoe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cubero, Francisco Javier</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gracia-Sancho, Jordi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Abdelbaky, Hanan H. ELSEVIER</subfield><subfield code="t">Identification of the antigenic region of</subfield><subfield code="d">2018</subfield><subfield code="d">official journal of the European Association for the Study of the Liver</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000433829</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:73</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:423-440</subfield><subfield code="g">extent:18</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jhep.2020.04.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">73</subfield><subfield code="j">2020</subfield><subfield code="e">2</subfield><subfield code="h">423-440</subfield><subfield code="g">18</subfield></datafield></record></collection>
|
| score |
7.3995314 |